Animal African Trypanosomiasis (AAT) is a fatal, parasitic wasting disease of livestock and wild animals in Sub-Saharan Africa.[@b0005] It is caused primarily by the two protozoan parasites *Trypanosoma congolense* (*T. congolense*) and *Trypanosoma vivax* (*T. vivax*)*,* which are transmitted by tsetse flies.[@b0005] AAT is responsible for 3 million cattle deaths annually and costs African livestock farmers approximately US\$ 1--5 billion per year.[@b0010] The current standard-of-care drugs, such as diminazene aceturate, isometamidium and homidium chloride, have been in use for several decades and are often ineffective with drug resistance becoming an increasing concern.[@b0005] No new trypanocides have been approved for use in cattle for many years. Initial screening of the Anacor Pharmaceuticals library of novel boron-containing compounds identified an active compound (**1**, [Fig. 1](#f0005){ref-type="fig"}), which had an IC~50~ = 5 nM against *T. congolense* and 69 nM against *T. vivax* while its enantiomer was much less active. A quick and simple modification on the amino acid side chain with an isopropyl group generated **2** ([Fig. 1](#f0005){ref-type="fig"}) with improved *in vitro* potency (IC~50~ = 2 nM against both *T. congolense* and *T. vivax*). This encouraging result prompted us to investigate this chemical series further. We designed and synthesized a series of novel benzoxaboroles (**3**--**71**, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}) to optimize anti-parasitic activity, physicochemical and *in vitro* ADME properties, and the pharmacokinetic profile. Specifically, these molecules were designed to examine the effects of oxaborole 3-substituent variation (**3** vs **2**, [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}), oxaborole 7-substituent variation (**4** vs **2**, [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}; **5** vs **20**--**27**, [Fig. 4](#f0020){ref-type="fig"}), substituent changes on the benzyl group (**5**--**19**, [Fig. 3](#f0015){ref-type="fig"}), modification of the amino acid (**28**--**32**, [Fig. 5](#f0025){ref-type="fig"}), heteroaromatic methyl esters (**33**--**48**, [Fig. 6](#f0030){ref-type="fig"}), introduction of water-solubilizing scaffolds to the benzyl group (**49**--**54**, [Fig. 7](#f0035){ref-type="fig"}) and aliphatic esters (**55**--**71**, [Fig. 8](#f0040){ref-type="fig"}). Herein, we report the synthesis and antiparasitic activity against *T. congolense* and *T. vivax* of these novel compounds.Fig. 1Chemical structures of early hits (**1** and **2**).Fig. 2Structures of benzoxaboroles with additional 3,3-Me~2~ (**3**) or 7-Me (**4**) modification as compared to analog **2**.Fig. 3Structures of benzoxaboroles with variation of substituents on the benzyl ring (**5**--**19**) as compared to analog **4**.Fig. 4Structures of benzoxaboroles with variation of 7-substituents on the benzene ring (**20**--**27**) as compared to analog **5**.Fig. 5Structures of benzoxaboroles with variation on the amino acid side chain (**28**--**32**) as compared to analog **5**.Fig. 6Structures of benzoxaboroles with variation of the left side arylmethyl groups (**33**--**48**) as compared to analog **5**.Fig. 7Structures of benzoxaboroles with water-solubilizing scaffolds on the benzyl ring (**49**--**54**) as compared to analog **5**.Fig. 8Structures of benzoxaboroles with variation of the left side aliphatic ester groups (**55**--**71**) as compared to analog **5**.

Compounds **1**--**71** were convergently synthesized from three building blocks: the left side alcohols (**72**), amino acid linkers (**73**) and benzoxaborole 6-carboxylic acids (**76**).[@b0015], [@b0020] The general synthetic route is shown in [Scheme 1](#f0045){ref-type="fig"}. Reaction of alcohols **72** with *N*-Boc protected amino acids **73** gave ester intermediates **74**, which were treated with dry hydrogen chloride to generate ester amine salts **75**. Condensation of these amine salts **75** with benzoxaborole 6-carboxylic acids **76** provided the final compounds **1**--**71**.Scheme 1General route for syntheses of **1**--**71**. Reagents and conditions: (a) DCC, DMAP, DCM, 0--20 °C, 16 h; (b) HCl/EtOAc, 20 °C, 5 h; (c) HOBt, EDCI, TEA, DCM, 0--20 °C, 15 h.

[Scheme 2](#f0050){ref-type="fig"} illustrates the synthesis of 1-hydroxy-7-methyl-1,3-dihydrobenzo\[*c*\]\[1,2\]oxaborole-6-carboxylic acid (**83**) as an example of key boron intermediates. Esterification of the acid **77** produced the ester **78**, which was formylated to yield **79**. Treatment of **79** with trifluoromethyl sulfonyl anhydride afforded the triflate compound **80**, which was converted to the pinacol boron intermediate **81**. Reduction of **81** and subsequent cyclization under aqueous acidic conditions generated the benzoxaborole ester **82**. Hydrolysis of the ester group in **82** afforded the acid **83**. The experimental procedures for the synthesis of **5** are described in the reference and note section.[@b0025]Scheme 2Synthetic route for preparation of **83**. Reagents and conditions: (a) H~2~SO~4~, EtOH, reflux, 24 h; (b) MgCl~2~, (CH~2~O)~n~, TEA, THF, reflux, 14 h; (c) Tf~2~O, pyridine, DMAP, DCM, 0--15 °C, 1 h; (d) Pin~2~B~2~, KOAc, Pd(dppf)Cl~2~, 1,4-dioxane, N~2~, 85 °C, 15 h; (e) NaBH~4~, MeOH, THF, 0--15 °C, 1 h, then HCl, H~2~O; (f) NaOH,H~2~O, 40 °C, 3 h, then HCl for acidification.

Activity of compounds **1**--**71** against *T. congolense* and *T. vivax* was determined using the whole cell assays as described ^6^ and their IC~50~ values are summarized in [Table 1](#t0005){ref-type="table"}.Table 1Activity of compounds **1**--**71** against *T. congolense* (*T. c.*) and *T. vivax* (*T. v.*).[a](#tblfn1){ref-type="table-fn"}CompoundIC~50~ (nM)CompoundIC~50~ (nM)*T. c.T. v.T. c.T. v.***1**4.969**37**0.780.50**2**2.02.0**38**0.680.31**3**25809190**39**0.570.24**4**0.460.79**40**0.270.50**5**0.141.3**41**0.780.11**6**0.472.9**42**0.200.19**7**0.590.10**43**0.062NT[b](#tblfn2){ref-type="table-fn"}**8**0.280.07**44**5000980**9**0.180.10**45**0.370.33**10**0.222.7**46**0.420.24**11**0.1624**47**0.200.081**12**0.3119**48**\<0.0050.71**13**0.230.04**49**0.3968**14**0.100.06**50**0.320.48**15**0.150.05**51**0.250.21**16**0.080.07**52**1.30.29**17**0.210.04**53**0.510.35**18**0.200.06**54**1.00.37**19**0.610.44**55**4.23.3**20**3.01.0**56**5.214**21**28NT[b](#tblfn2){ref-type="table-fn"}**57**0.460.26**22**0.670.92**58**0.660.69**23**3751**59**0.700.52**24**0.110.05**60**\<0.0050.78**25**3.04.7**61**0.360.21**26**2.30.05**62**0.380.16**27**3.90.71**63**0.390.09**28**0.120.38**64**2.30.78**29**0.260.10**65**9.41.2**30**0.090.25**66**5.94.1**31**0.1318**67**0.430.79**32**0.452.5**68**1.837**33**0.2826**69**0.471.6**34**0.140.07**70**0.342.28**35**0.150.09**71**0.20.14**36**0.260.14[^1][^2]

Lead compound **2** exhibited an IC~50~ of 2 nM against both *T. congolense* and *T. vivax*. The 3,3-dimethyl analog **3** was essentially inactive (IC~50~ = 2580 nM against *T. c.* and 9190 nM against *T. v.*) but better activity was observed for the 7-methyl analog **4** (IC~50~ = 0.46 nM against *T. c.* and 0.79 nM against *T. v.*). We focused future SAR development on compounds incorporating the 7-methyl group, as *in vivo* activity of **4** was superior to that observed for **2** *(vide infra)*. A wide range of substituents, such as halogens, trifluoromethyl, trifluoromethoxy, cyano and methylsulfonyl (**5**--**19** in [Fig. 3](#f0015){ref-type="fig"}) on the benzyl ring were introduced to examine their effects on the antiparasitic activity. The majority of these fifteen compounds, with exception of **11** and **12**, were very potent showing IC~50~ values around 1 nM (see [Table 1](#t0005){ref-type="table"}). We next explored variation of the substituent at the 7-position of benzoxaborole (**20**--**27** in [Fig. 4](#f0020){ref-type="fig"}). The difluoromethyl (**22**) and ethyl (**24**) analogs had similar activity to that of **5,** but the electron-withdrawing fluoro (**21**) and trifluoromethyl (**23**) analogs were of significantly reduced potency. The amino acid linker was also modified ([Fig. 5](#f0025){ref-type="fig"}), with the cyclopropyl (**28**), 2-hydroxyisopropyl (**29**), 2-fluoroisopropyl (**30**) and spirocyclobutyl (**32**) analogs exhibiting potency similar to **5**, but the spirocyclopropyl analog (**31**) exhibited decreased activity against *T. v.* parasite. Replacement of the 4-fluorophenyl in **5** with various heteroaryl groups (**33**--**48**, [Fig. 6](#f0030){ref-type="fig"}) resulted in the excellent activity in all cases except the NH-imidazole analog **44**. Introduction of basic nitrogen-containing groups on the benzyl ester (**49**--**54**, [Fig. 7](#f0035){ref-type="fig"}) provided compounds **50**--**54** that were generally similar to **5**. Lastly, aliphatic and heterocyclic esters (**55**--**71**, [Fig. 8](#f0040){ref-type="fig"}) were synthesized and many of these had IC~50~ values less than 1 nM as shown in [Table 1](#t0005){ref-type="table"}.

Selected compounds were screened in both mouse and bovine *in vitro* metabolic stability assays (mouse S9 and bovine S9), as summarized in [Table 2](#t0010){ref-type="table"}. These two species were chosen because the primary *in vivo* assays were conducted in mice, and the target animal of this research program is cattle. As shown in [Table 2](#t0010){ref-type="table"}, out of 36 compounds tested, 27 compounds had Cl~int~ \< 10 µL/min/mg protein in both mouse and bovine S9 assays suggesting moderate to excellent *in vitro* metabolic stability. We evaluated the efficacy of selected compounds in two *in vivo* mouse models of infection, against *T. congolense* and *T. vivax*, respectively. Mice were infected with either 1 × 10^5^ *T. c.* parasites or 1 × 10^4^ *T. v.* parasites, and then treated with a test compound via intraperitoneal administration for 1, 2 or 4 consecutive days. The mice were then monitored for the presence of parasitemia for up to 60 days post treatment.[@b0035] We tested in *T. c.* model first, then followed up with *T. v.* for interesting compounds. As shown in [Table 2](#t0010){ref-type="table"}, the 7-methyl analog **4** was superior to the 7-unsubstituted analog **2** in both *T. c.* and *T. v.* mouse models of infection. Of the 38 compounds tested with the *in vivo* mouse models, seven compounds (**5**, **8**, **33**, **34**, **49**, **62** and **71**) demonstrated ≥50% curative efficacy in the *T. c*.-infected mouse model and 100% curative efficacy in the *T. v*.-infected mouse model, when tested as a single dose of 10 mg/kg. To select further from these seven compounds, four (**5**, **8**, **33** and **71**) had ≥75% curative efficacy in the *T. c*.-infected mouse model at a single dose of 10 mg/kg, and two (**5** and **8**) showed 100% curative efficacy. These two compounds were further tested at a single 5 mg/kg dose, but were unable to cure the *T. c.*-infected mice. We selected compound **5** (**AN11736**) to progress to exploratory studies to determine the efficacy and safety in a preliminary formulation against induced infections of *T. vivax* and *T. congolense* in cattle.[@b0040] **AN11736** demonstrated 100% curative efficacy with a single intramuscular injection of 10 mg/kg against both *T. congolense* and *T. vivax* in cattle.Table 2*In vitro* metabolic stability and *in vivo* mouse efficacy of selected compounds.[a](#tblfn3){ref-type="table-fn"}CompoundCl~int~ (µL/min/mg protein)Efficacy in mouse model[b](#tblfn4){ref-type="table-fn"}Mouse S9Bovine S9*T. c.T. v.***2**NT[c](#tblfn5){ref-type="table-fn"}NT[c](#tblfn5){ref-type="table-fn"}0/5 (2 × 10)5/5 (4 × 10)\
1/5 (1 × 10)**4**NT[c](#tblfn5){ref-type="table-fn"}NT[c](#tblfn5){ref-type="table-fn"}4/5 (2 × 10)5/5 (2 × 10)\
4/4 (1 × 10)**5**5.49.35/5 (2 × 10)\
4/4 (1 × 10)\
0/4 (1 × 5)5/5 (2 × 10)\
5/5 (1 × 10)\
4/4 (1 × 10)**6**179.10/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**8**7.95.64/4 (1 × 10)\
0/4 (1 × 5)4/4 (1 × 10)**14**9.12.70/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**16**158.94/4 (2 × 10)\
1/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**17**14100/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**18**9.73.11/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**19**2.61.30/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**20**1.51.30/5 (4 × 10)NT[c](#tblfn5){ref-type="table-fn"}**21**\<1\<11/4 (2 × 10)4/4 (2 × 10)**22**1.40.90/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**24**21231/4 (2 × 10)NT[c](#tblfn5){ref-type="table-fn"}**26**32320/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**29**\<1\<10/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**30**3.73.10/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**31**\<1\<10/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**33**6.32.03/4 (1 × 10)4/4 (1 × 10)**34**11.84.82/4 (1 × 10)4/4 (1 × 10)**35**5.27.80/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**39**1.63.90/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**41**1.31.80/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**46**7.47.01/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**47**4.8100/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**48**4.0231/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**49**1.54.02/4 (1 × 10)4/4 (1 × 10)**50**8.612.71/4 (1 × 10)4/4 (1 × 10)**51**1.85.00/4 (1 × 10)4/4 (1 × 10)**52**1.86.00/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**53**5.46.80/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**54**5.53.80/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**55**\<13.10/4 (1 × 10)NT[c](#tblfn5){ref-type="table-fn"}**62**10202/4 (1 × 10)4/4 (1 × 10)**63**0.91.51/4 (1 × 10)4/4 (1 × 10)**69**0.70.61/4 (1 × 10)1/4 (1 × 10)**70**1.50.31/4 (1 × 10)4/4 (1 × 10)**71**6.48.13/4 (1 × 10)4/4 (1 × 10)[^3][^4][^5]

In summary, a novel series of [*l*]{.smallcaps}-valinate amide benzoxaboroles was discovered to be active against *T. congolense* and *T. vivax*, which are the main causative agents of Animal African Trypanosomiasis (AAT) in cattle. Two compounds (**5** and **8**) showed 100% curative efficacy in both *T. c*.- and *T. v.*-infected mice with a single dose of 10 mg/kg. Compound **5** (**AN11736**) demonstrated 100% curative efficacy with a single IM dose of 10 mg/kg against both *T. congolense* and *T. vivax* in cattle for a duration of 100 days. **AN11736**, as a novel chemical entity, was selected as a potential developmental candidate for the treatment of AAT.

The research was conducted with a grant from the Global Alliance for Livestock Veterinary Medicines (GALVmed) and funded by the Bill & Melinda Gates Foundation \[OPP1093639\] and the UK Government. The findings and conclusions contained are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation or the UK Government.

[^1]: Experimental procedures are described in the reference and note section.[@b0030]

[^2]: NT = Not tested.

[^3]: Methods for testing compound efficacy in mouse models are described in the reference and note section.[@b0035]

[^4]: The efficacy data in the table is presented as n/m (q × 10), where n = number of mice survived, m = total number of mice in the study group, q = how many time dosed, and 10 = 10 mg/kg.

[^5]: NT = Not tested.
